The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis
Authors:
- Viviana A. Ruiz-PozoVRViviana A. Ruiz-Pozo
- Rafael Tamayo-TrujilloRTRafael Tamayo-Trujillo
- Santiago Cadena-UllauriSCSantiago Cadena-Ullauri
- Evelyn Frias-ToralEvelyn Frias-Toral
- Patricia Guevara-RamírezPGPatricia Guevara-Ramírez
- Elius Paz-CruzEPElius Paz-Cruz
- Sebastián ChapelaSCSebastián Chapela
- Martha MontalvánMMMartha Montalván
- Tania Morales-LópezTMTania Morales-López
- Daniel Simancas-RacinesDSDaniel Simancas-Racines
- Ana Karina ZambranoAZAna Karina Zambrano
Open Access
Abstract
Parkinson’s disease (PD) is a degenerative condition resulting from the loss of dopaminergic neurons. This neuronal loss leads to motor and non-motor neurological symptoms. Most PD cases are idiopathic, and no cure is available. Recently, it has been proposed that insulin resistance (IR) could be a central factor in PD development. IR has been associated with PD neuropathological features like α-synuclein aggregation, dopaminergic neuronal loss, neuroinflammation, mitochondrial dysfunction, and autophagy. These features are related to impaired neurological metabolism, neuronal death, and the aggravation of PD symptoms. Moreover, pharmacological options that involve insulin signaling improvement and dopaminergic and non-dopaminergic strategies have been under development. These drugs could prevent the metabolic pathways involved in neuronal damage. All these approaches could improve PD outcomes. Also, new biomarker identification may allow for an earlier PD diagnosis in high-risk individuals. This review describes the main pathways implicated in PD development involving IR. Also, it presents several therapeutic options that are directed at insulin signaling improvement and could be used in PD treatment. The understanding of IR molecular mechanisms involved in neurodegenerative development could enhance PD therapeutic options and diagnosis.Keywords
Funding Information
- universidad ute
This publication has 160 references indexed in Scilit:
- Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in SerumPLOS ONE, 2012
- Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemiaJournal of Neuroinflammation, 2012
- The Mitochondrial Chaperone Protein TRAP1 Mitigates α-Synuclein ToxicityPLOS Genetics, 2012
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's DiseaseCell, 2011
- Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivoNeuroscience Letters, 2010
- Profile of Cognitive Impairment in Parkinson's DiseaseBrain Pathology, 2010
- Medical records documentation of constipation preceding Parkinson diseaseNeurology, 2009
- Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson diseaseJournal of Clinical Investigation, 2008
- α-Synuclein Locus Triplication Causes Parkinson's DiseaseScience, 2003
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997